BIO lawyers up
The Biotechnology Industry Organization appoints Sandra Dennis to the newly created position of Deputy General Counsel for Healthcare Regulatory Affairs. The addition of Dennis serves to "enhance BIO's advocacy for a regulatory environment that allows biotechnology industry to bring ... technologies to market," BIO President Jim Greenwood says in a Jan. 9 release. The trade association is bolstering its regulatory affairs department at a time many anticipate increased Congressional interest in the establishment of a regulatory framework for approval of generic biologics (1"The Pink Sheet" Nov. 13, 2006, p. 3). Dennis comes to BIO from Morgan, Lewis & Bockius' FDA/Healthcare Regulation practice group, where she focused on regulatory, legislative, policy and corporate issues...
You may also be interested in...
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act
With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.
India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.